Takeda Pharmaceutical Company Limited is a global, research-driven biopharmaceutical company based in Japan. Founded in 1781, the company discovers, develops, manufactures, and markets prescription medicines and vaccines. Its core therapeutic areas include gastroenterology and inflammation, oncology, neuroscience, rare genetic and hematology diseases, plasma-derived therapies, and vaccines.
Takeda operates an international R&D and manufacturing network that spans small‑molecule and biologic modalities. Capabilities include medicinal chemistry, process and scale-up chemistry, biologics development and production, plasma fractionation, and formulation and fill‑finish. The company produces active pharmaceutical ingredients (APIs) and finished dosage forms for global markets, supplying healthcare systems in numerous countries. Its activities intersect with the broader chemical value chain through API synthesis, process development, quality control, and compliance with global cGMP and regulatory standards.
Also known as 武田薬品, Takeda Pharmaceuticals, 武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha, Takeda Yakuhin Kōgyō Kabushiki Kaisha, and Takeda China.
chemXplore tracks 6 projects involving Takeda, of which 2 are active.
Takeda's role on them: Owner, Investor / Financier, Operator, Developer, and Technology / equipment supplier.
2 new construction.
1 of the active projects carry no start-up date yet.
Licensors are recorded on 1 of these 2 projects For subscribers
Targeting: Coagulation factor IX (1)
FDA granted priority review to an oral TYK2 inhibitor after Phase 3 data from nearly 3,000 patients showed rapid, durable skin clearance; PDUFA target Q1 2027.
First-in-class hepcidin mimetic approved for adult PV erythrocytosis; Phase 3 VERIFY showed hematocrit control, reduced phlebotomy and improved fatigue.
Japan clears the first oral OX2R agonist to address underlying orexin deficiency for adults with narcolepsy type 1.
First-in-class oral OX2R agonist for adults with NT1; Phase 3 showed symptom-wide benefit including daytime sleepiness and cataplexy; DEA scheduling pending before distribution.
Solid quarter: revenue +10.2% AER; adjusted free cash flow JPY 68.6bn; launch prep for ORZEYFUL, rusfertide and zasocitinib; FY2026 outlook unchanged.
China approves first oral OX2R-selective orexin agonist for narcolepsy type 1 for patients 16 and older; Phase 3 trials reported improvements in sleepiness and cataplexy.
Phase 3 secondary data show ~75% scalp and ~70% palmoplantar clearance at week 16; significant nail improvement; responses sustained to week 24; common AEs: URTI, nasopharyngitis, acne.
Fractionation license granted; $30M pilot to open plasma donation centers and assess local PDMP manufacturing, first donation center expected 2027.
